Market Place
Sourcing Support
AbbVie`s Rinvoq Produces Stellar Results in Alopecia Study
05 Aug 2025 //
FIERCE PHARMA
AbbVie Halts IL-1 Asset Development for Ulcerative Colitis
31 Jul 2025 //
FIERCE BIOTECH
AbbVie Celebrates as Skyrizi and Rinvoq Generate Billions
31 Jul 2025 //
BIOSPACE
AbbVie`s Financial Results for Q2 2025 Released
31 Jul 2025 //
PR NEWSWIRE
AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal
31 Jul 2025 //
REUTERS
AbbVie`s Phase 3 Trial of Upadacitinib for Alopecia Areata
30 Jul 2025 //
PRESS RELEASE
Lilly`s BTK Jaypirca Outperforms Imbruvica in Trials
30 Jul 2025 //
FIERCE PHARMA
Abbvie Submitted sNDA for Venetoclax in Untreated CLL
30 Jul 2025 //
PRESS RELEASE
AbbVie, Gilead, GSK Support Annual Hepatitis Elimination Drive
29 Jul 2025 //
FIERCE PHARMA
AbbVie awarded $56M in Botox patent infringement case
23 Jul 2025 //
FIERCE PHARMA
AbbVie Wins $56M in Botox Patent Case
22 Jul 2025 //
FIERCE PHARMA
Botox Cosmetic Picks Entrepreneurs for Confidence Project
22 Jul 2025 //
PR NEWSWIRE
6 Companies Hiring in Illinois
17 Jul 2025 //
BIOSPACE
AbbVie`s Skyrizi, Novo`s Wegovy Top Q2 TV Ad Spending
16 Jul 2025 //
FIERCE PHARMA
AbbVie & IGI Ink Global Deal For ISB 2001 Licensing Rights
12 Jul 2025 //
PRESS RELEASE
AbbVie to buy Capstan for up to $2.1B in Immunology Push
01 Jul 2025 //
PRESS RELEASE
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
30 Jun 2025 //
PR NEWSWIRE
Turnstone, once allied with AbbVie, accepts $8M Xoma buyout
30 Jun 2025 //
FIERCE BIOTECH
Despite revision, UCPMP remains toothless: Alleges FMRAI
23 Jun 2025 //
PHARMABIZ
AbbVie Declares Quarterly Dividend
20 Jun 2025 //
PRESS RELEASE
AbbVie`s Migraine Drug Meets Main Goal in Head-To-Head Study
19 Jun 2025 //
PRESS RELEASE
AbbVie Shares Update on Verona Trial for MDS Patients
16 Jun 2025 //
PR NEWSWIRE
AbbVie says blood cancer drug fails late-stage trial
16 Jun 2025 //
REUTERS
AbbVie Secures FDA Approval for Expanded Use of Mavyret
12 Jun 2025 //
PRESS RELEASE
AbbVie to Present at Goldman Sachs Healthcare Conference
03 Jun 2025 //
PRESS RELEASE
Abbvie Invites Migraine Sufferers to Enter Career Catalyst Award
03 Jun 2025 //
PRESS RELEASE
AbbVie flies the W against cancer with Chicago Cubs partnership
30 May 2025 //
FIERCE PHARMA
AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
30 May 2025 //
PR NEWSWIRE
AbbVie Showcases Data on Solid Tumors and Blood Cancers at ASCO
28 May 2025 //
PRESS RELEASE
AbbVie Showcases Data on Solid Tumors and Blood Cancers at ASCO
27 May 2025 //
PRESS RELEASE
AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal
15 May 2025 //
PRESS RELEASE
US FDA approves AbbVie`s drug for a type of lung cancer
15 May 2025 //
PRESS RELEASE
AbbVie plant workers in Ireland plan to strike over pay issue
14 May 2025 //
FIERCE PHARMA
AbbVie again leads doctors` perception of immunology drugmakers
12 May 2025 //
FIERCE PHARMA
Techbio Pioneer Etcembly Signs Deal With DJS Antibodies
12 May 2025 //
BUSINESSWIRE
AbbVie`s Biologics Skyrizi Receives Suppl Approval in US
07 May 2025 //
FDA
AbbVie to Present at Bank of America Healthcare Conference
06 May 2025 //
PRESS RELEASE
AbbVie’s Skyrizi retakes top TV ad spending spot in April
05 May 2025 //
FIERCE PHARMA
Botox Backs Entrepreneurs via Confidence Project
01 May 2025 //
PR NEWSWIRE
Rinvoq Recieves FDA approved for Giant Cell Arteritis
29 Apr 2025 //
PRESS RELEASE
AbbVie plots $10B US outlay as pharma tariff threat looms
26 Apr 2025 //
FIERCE PHARMA
AbbVie to First-Quarter 2025 Earnings Conference Call
26 Apr 2025 //
PRESS RELEASE
AbbVie Submits BLA for TrenibotE for Treatment of Glabellar
25 Apr 2025 //
PRESS RELEASE
AbbVie launches Venetoclax in India for AML and CLL
21 Apr 2025 //
EXPRESSPHARMA
ThirtyFiveBio closes bridge round with new investment from AbbVie
15 Apr 2025 //
PRESS RELEASE
AbbVie Announces EMA Approval of Rinvoqa For Giant Cell Arteritis
09 Apr 2025 //
PRESS RELEASE
AbbVie cuts 2025 profit forecast on acquisition expenses
03 Apr 2025 //
REUTERS
AbbVie to Host First-Quarter 2025 Earnings Conference Call
31 Mar 2025 //
PR NEWSWIRE
Regulatory Condition Met for AbbVie-Gubra License Agreement
28 Mar 2025 //
ACCESSWIRE
AbbVie Highlights Oncology Advances at AACR Meeting 2025
27 Mar 2025 //
PRESS RELEASE
Allergan Aesthetic` Innovation, Science, Patient Focus at AMWC 2025
24 Mar 2025 //
PR NEWSWIRE
Genmab To Defend Against Trade Secret Claims By AbbVie
21 Mar 2025 //
GLOBENEWSWIRE
ELAHERE® Shows Consistent Survival Benefit in Ovarian Cancer
15 Mar 2025 //
PR NEWSWIRE
AbbVie &Gubra Announce License Agreement to Develop an Amylin Analog
03 Mar 2025 //
PRESS RELEASE
Epkinely Gets Japan MHLW Approval For R/R Follicular Lymphoma
20 Feb 2025 //
GLOBENEWSWIRE
UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness
14 Feb 2025 //
FIERCE PHARMA
AbbVie Declares Quarterly Dividend
13 Feb 2025 //
PR NEWSWIRE
AbbVie Commits $2.1B to Revolutionary Tumor-Fighting Tech
13 Feb 2025 //
PRESS RELEASE
FDA Approves EMBLAVEO For Complicated Intra-Abdominal Infections
08 Feb 2025 //
INDPHARMAPOST
FDA approves AbbVie-Pfizer`s treatment for abdominal infections
08 Feb 2025 //
REUTERS
